$VVOS
Vivos Therapeutics, Inc. Stock $vvos

$vvos Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222036000 Filed on December 20, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2022 Q2
Revenue	$3.950M	$4.246M	$4.184M
YoY Change	-10.11%	-6.6%	-6.96%
Cost Of Revenue	$1.566M	$100.0K	$100.0K
YoY Change	21.66%	-92.66%	-88.54%
Gross Profit	$2.384M	$2.496M	$2.588M
YoY Change	-23.28%	-21.58%	-28.59%
Gross Profit Margin	60.35%	58.78%	61.85%
Selling, General & Admin	$8.278M	$7.728M	$9.390M
YoY Change	-12.3%	-9.01%	25.36%
% of Gross Profit	347.23%	309.62%	362.83%
Research & Development		$100.0K	$100.0K
YoY Change		0.0%	0.0%
% of Gross Profit		4.01%	3.86%
Depreciation & Amortization	$169.0K	$200.0K	$200.0K
YoY Change	0.46%	3.9%	4.02%
% of Gross Profit	7.09%	8.01%	7.73%
Operating Expenses	$8.447M	$7.903M	$9.552M
YoY Change	-12.08%	-9.01%	24.29%
Operating Profit	-$6.063M	-$5.407M	-$6.964M
YoY Change	-6.73%	-1.74%	71.47%
Interest Expense	$0.00
YoY Change	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$26.00K	-$27.00K	-$28.00K
YoY Change	188.89%
Pretax Income	-$6.089M	-$5.434M	-$6.992M
YoY Change	-17.64%	-0.35%	72.96%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$6.089M	-$5.434M	-$6.992M
YoY Change	-17.64%	-0.35%	72.96%
Net Earnings / Revenue	-154.15%	-127.98%	-167.11%
Basic Earnings Per Share		-$0.26	-$0.33
Diluted Earnings Per Share	-$0.26	-$255.9K	-$329.3K
COMMON SHARES
Basic Shares Outstanding	23.01M shares	21.23B shares	21.23B shares
Diluted Shares Outstanding		849.4K shares	21.23M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.519M	$6.719M	$12.66M
YoY Change	-85.36%	-76.45%	-62.98%
Cash & Equivalents	$3.500M	$6.700M	$12.70M
Short-Term Investments
Other Short-Term Assets	$1.448M	$2.116M	$2.061M
YoY Change	-30.75%	32.09%	23.2%
Inventory
Prepaid Expenses
Receivables	$457.0K	$866.0K	$791.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.424M	$9.701M	$15.51M
YoY Change	-80.15%	-71.49%	-60.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.082M	$3.044M	$3.109M
YoY Change	9.1%	17.03%	35.7%
Goodwill	$2.843M	$2.843M	$2.843M
YoY Change	0.0%
Intangibles	$302.0K	$312.0K	$322.0K
YoY Change	-11.44%
Long-Term Investments
YoY Change
Other Assets	$374.0K	$372.0K	$373.0K
YoY Change	5.06%	4.58%	-0.44%
Total Long-Term Assets	$8.296M	$8.699M	$8.862M
YoY Change	30.34%	24.4%	30.95%
TOTAL ASSETS
Total Short-Term Assets	$5.424M	$9.701M	$15.51M
Total Long-Term Assets	$8.296M	$8.699M	$8.862M
Total Assets	$13.72M	$18.40M	$24.38M
YoY Change	-59.27%	-55.15%	-47.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.411M	$644.0K	$1.252M
YoY Change	53.37%	-8.03%	-3.6%
Accrued Expenses	$1.912M	$2.179M	$2.618M
YoY Change	-32.98%	-13.99%	-0.68%
Deferred Revenue	$2.926M	$2.401M	$2.080M
YoY Change	21.97%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.813M	$5.964M	$6.694M
YoY Change	-9.27%	-27.22%	-28.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.106M	$2.581M	$2.842M
YoY Change	513.99%	616.94%	692.97%
Total Long-Term Liabilities	$2.106M	$2.581M	$2.842M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.813M	$5.964M	$6.694M
Total Long-Term Liabilities	$2.106M	$2.581M	$2.842M
Total Liabilities	$8.900M	$8.500M	$9.500M
YoY Change	9.2%	-0.64%	-1.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.50M	-$73.40M	-$67.90M
YoY Change	42.99%
Common Stock	$2.000K	$2.000K	$2.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.801M	$9.855M	$14.84M
YoY Change
Total Liabilities & Shareholders Equity	$13.72M	$18.40M	$24.38M
YoY Change	-59.27%	-55.15%	-47.19%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2022 Q2
OPERATING ACTIVITIES
Net Income	-$6.089M	-$5.434M	-$6.992M
YoY Change	-17.64%	-0.35%	72.96%
Depreciation, Depletion And Amortization	$169.0K	$200.0K	$200.0K
YoY Change	0.46%	3.9%	4.02%
Cash From Operating Activities	-$3.000M	-$5.842M	-$4.663M
YoY Change	-27.22%	43.95%	26.21%
INVESTING ACTIVITIES
Capital Expenditures	$200.0K	-$100.0K	-$504.0K
YoY Change	-152.27%	-77.3%	-61.61%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Cash From Investing Activities	-$200.0K	-$100.0K	-$504.0K
YoY Change	-47.69%	-76.85%	-67.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change	-100.0%	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-3.000M	-5.842M	-4.663M
Cash From Investing Activities	-200.0K	-100.0K	-504.0K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-3.200M	-5.942M	-5.167M
YoY Change	-28.97%	4.91%	-125.65%
FREE CASH FLOW
Cash From Operating Activities	-$3.000M	-$5.842M	-$4.663M
Capital Expenditures	$200.0K	-$100.0K	-$504.0K
Free Cash Flow	-$3.200M	-$5.742M	-$4.159M
YoY Change	-14.43%	58.71%	74.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y1M6D
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001716166
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	us-gaap	Tenant Improvements TenantImprovements		usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q2	VVOS	Stock Issued During Period Value Issued For Services Fair Value Of Warrants StockIssuedDuringPeriodValueIssuedForServicesFairValueOfWarrants		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets		usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
	VVOS	Noncash Lease Expense NoncashLeaseExpense		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	VVOS	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt		usd
	VVOS	Forgiveness Of Indebtness Income ForgivenessOfIndebtnessIncome		usd
	VVOS	Increase Decrease In Tenant Improvement Allowance IncreaseDecreaseInTenantImprovementAllowance		usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	VVOS	Forgiveness Of Indebtedness Income Principal ForgivenessOfIndebtednessIncomePrincipal		usd
	VVOS	Fair Value Of Warrants Issued In Asset Purchase FairValueOfWarrantsIssuedInAssetPurchase		usd
	VVOS	Fair Value Of Warrants Issued In Business Acquisition FairValueOfWarrantsIssuedInBusinessAcquisition		usd
	VVOS	Fair Value Of Warrants Issued To Underwriters In Connection With Followon Offering FairValueOfWarrantsIssuedToUnderwritersInConnectionWithFollowonOffering		usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39796
	dei	Entity Registrant Name EntityRegistrantName	Vivos Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3224056
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7921 Southpark Plaza
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Address City Or Town EntityAddressCityOrTown	Littleton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80120
	dei	City Area Code CityAreaCode	(866)
	dei	Local Phone Number LocalPhoneNumber	908-4867
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	VVOS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23012119	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6719000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24030000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	449000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	593000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	866000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1203000	usd
CY2021Q4	us-gaap	Tenant Improvements TenantImprovements	516000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2116000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1575000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	9701000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	27324000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	2843000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3044000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2825000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2128000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	312000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	341000	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	372000	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	356000	usd
CY2022Q3	us-gaap	Assets Assets	18400000	usd
CY2021Q4	us-gaap	Assets Assets	33689000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	644000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	920000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2179000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2853000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2401000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2399000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1265000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	446000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	72000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	294000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5964000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7509000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	180000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2401000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	641000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8545000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	8150000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23012119	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23012119	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23012119	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23012119	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83233000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81160000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73380000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55623000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9855000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25539000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18400000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33689000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4246000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4546000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12074000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12491000	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1750000	usd
CY2021Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1363000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	4439000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	2994000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	2496000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	3183000	usd
	us-gaap	Gross Profit GrossProfit	7635000	usd
	us-gaap	Gross Profit GrossProfit	9497000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6622000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6517000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22118000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17669000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1106000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1976000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3985000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4234000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	175000	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	193000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	565000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	7903000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	8686000	usd
	us-gaap	Operating Expenses OperatingExpenses	26603000	usd
	us-gaap	Operating Expenses OperatingExpenses	22468000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5407000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5503000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18968000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12971000	usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	36000	usd
CY2021Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	152000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	10000	usd
	VVOS	Gain Loss On Ppp Loan Forgiveness GainLossOnPPPLoanForgiveness	-1287000	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	9000	usd
CY2021Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	59000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	77000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	86000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5434000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5453000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17756000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12895000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-5434000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5453000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17756000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12895000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5434000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5453000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17756000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12895000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20826499000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20634092000	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16917000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	usd
CY2021Q1	VVOS	Stock Issued During Period Value Issued For Services Fair Value Of Warrants StockIssuedDuringPeriodValueIssuedForServicesFairValueOfWarrants	232000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	136000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	434000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3399000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	14340000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25362000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	172000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	648000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4043000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	36479000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1113000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5453000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	32469000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25539000	usd
CY2022Q1	VVOS	Stock Issued During Period Value Issued For Services Fair Value Of Warrants StockIssuedDuringPeriodValueIssuedForServicesFairValueOfWarrants	222000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	609000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5331000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	21039000	usd
CY2022Q2	VVOS	Stock Issued During Period Value Issued For Services Fair Value Of Warrants StockIssuedDuringPeriodValueIssuedForServicesFairValueOfWarrants	131000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	661000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-6992000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	14839000	usd
CY2022Q3	VVOS	Stock Issued During Period Value Issued For Services Fair Value Of Warrants StockIssuedDuringPeriodValueIssuedForServicesFairValueOfWarrants	100000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	350000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-5434000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	9855000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17756000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12895000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1621000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2195000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-36000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	565000	usd
	VVOS	Noncash Lease Expense NoncashLeaseExpense	383000	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	452000	usd
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	232000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	20000	usd
	VVOS	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt	22000	usd
	VVOS	Forgiveness Of Indebtness Income ForgivenessOfIndebtnessIncome	1265000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-337000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2402000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-376000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	196000	usd
	VVOS	Increase Decrease In Tenant Improvement Allowance IncreaseDecreaseInTenantImprovementAllowance	516000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	541000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	929000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	17000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	47000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-276000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-81000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-644000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	797000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	261000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	182000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	758000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16587000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11613000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	724000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2014000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	225000	usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	13000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-724000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2226000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27930000	usd
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	1500000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2238000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	25000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24167000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17311000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10328000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24030000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18206000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6719000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28534000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
	us-gaap	Interest Paid Net InterestPaidNet	10000	usd
	VVOS	Forgiveness Of Indebtedness Income Principal ForgivenessOfIndebtednessIncomePrincipal	1265000	usd
	VVOS	Fair Value Of Warrants Issued In Asset Purchase FairValueOfWarrantsIssuedInAssetPurchase	136000	usd
	VVOS	Fair Value Of Warrants Issued In Business Acquisition FairValueOfWarrantsIssuedInBusinessAcquisition	172000	usd
	VVOS	Fair Value Of Warrants Issued To Underwriters In Connection With Followon Offering FairValueOfWarrantsIssuedToUnderwritersInConnectionWithFollowonOffering	1486000	usd
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2152000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	312000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	341000	usd
	VVOS	Cost Of Service Expense CostOfServiceExpense	45000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zgP5a3MtzvG2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zz4G7dQWI584">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on existing facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, assessing collectability on accounts receivable, the determination of customer life and breakage related to recognizing revenue for VIP contracts, notes receivable, impairment of goodwill and long-lived assets; valuation assumptions for assets acquired in business combinations; valuation assumptions for stock options, warrants and equity instruments issued for goods or services; deferred income taxes and the related valuation allowances; and the evaluation and measurement of contingencies. Additionally, the full impact of COVID-19 is unknown and cannot be reasonably estimated. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2181000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	522000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	200000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	148000	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	69000	usd
	us-gaap	Lease Cost LeaseCost	410000	usd
	us-gaap	Lease Cost LeaseCost	522000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	100000	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	100000	usd
	us-gaap	Payments For Rent PaymentsForRent	400000	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50 percent likelihood
CY2021	us-gaap	Profit Loss ProfitLoss	20300000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55600000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12900000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11600000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8500000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6700000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4246000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4546000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12074000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12491000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	39000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	39000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	39000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	9000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2399000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2938000	usd
CY2022Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1183000	usd
CY2021Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1617000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1421000	usd
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1753000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2161000	usd
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2802000	usd
CY2022Q2	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1556000	usd
CY2021Q2	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	3664000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1320000	usd
CY2021Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-2351000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2397000	usd
CY2021Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4115000	usd
CY2022Q3	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1950000	usd
CY2021Q3	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1909000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1766000	usd
CY2021Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-2327000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2581000	usd
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3697000	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2400000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	200000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23000	usd
CY2022Q3	VVOS	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	163000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	312000	usd
	us-gaap	Payments For Rent PaymentsForRent	500000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4637000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4068000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1593000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1243000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3044000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2825000	usd
CY2022Q3	us-gaap	Area Of Land AreaOfLand	15000	sqft
CY2022Q3	us-gaap	Depreciation Depreciation	200000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	100000	usd
	us-gaap	Depreciation Depreciation	500000	usd
	us-gaap	Depreciation Depreciation	300000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	2843000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1300000	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0100	pure
CY2020Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-05-05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2493000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2493000	usd
CY2022Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1187000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1397000	usd
CY2022Q3	VVOS	Accrued Legal And Other AccruedLegalAndOther	667000	usd
CY2021Q4	VVOS	Accrued Legal And Other AccruedLegalAndOther	990000	usd
CY2022Q3	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	325000	usd
CY2021Q4	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	466000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2179000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2853000	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2851000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.00
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2302000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.84
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	570000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	969000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.23
	VVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualTerm2	P4Y8M19D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	523000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	200000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.25
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	200000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.65
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2898000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.56
	VVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2871000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.96
	VVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y3M18D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2180000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y1M6D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1712000	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y8M12D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	148000	usd
CY2022Q3	us-gaap	Share Price SharePrice	1.45
CY2021Q3	us-gaap	Share Price SharePrice	4.96
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.031	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.35	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.41	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.45
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2022Q3	VVOS	Vested Warrants VestedWarrants	0	usd
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	69000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	410000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M4D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	141000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	683000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	705000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	654000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	564000	usd
CY2022Q3	VVOS	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	735000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3482000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	635000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2847000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-17756000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12895000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17756000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12895000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20634092000	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5664	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5407	shares

Files In Submission

Name	View Source	Status
0001493152-22-036000-index-headers.html	Edgar Link	pending
0001493152-22-036000-index.html	Edgar Link	pending
0001493152-22-036000.txt	Edgar Link	pending
0001493152-22-036000-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vvos-20220930.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
vvos-20220930_def.xml	Edgar Link	unprocessable
vvos-20220930_pre.xml	Edgar Link	unprocessable
vvos-20220930_lab.xml	Edgar Link	unprocessable
vvos-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VVOS
Vivos Therapeutics, Inc. Stock $vvos

2022 Q4 Form 10-Q Financial Statement

#000149315222036000 Filed on December 20, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS Vivos Therapeutics, Inc. Stock $vvos

2022 Q4 Form 10-Q Financial Statement

#000149315222036000 Filed on December 20, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS
Vivos Therapeutics, Inc. Stock $vvos